WO2012111187A1 - 皮膚コラーゲン産生促進剤 - Google Patents
皮膚コラーゲン産生促進剤 Download PDFInfo
- Publication number
- WO2012111187A1 WO2012111187A1 PCT/JP2011/068123 JP2011068123W WO2012111187A1 WO 2012111187 A1 WO2012111187 A1 WO 2012111187A1 JP 2011068123 W JP2011068123 W JP 2011068123W WO 2012111187 A1 WO2012111187 A1 WO 2012111187A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- menaquinone
- skin
- collagen production
- collagen
- production promoter
- Prior art date
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
- A61K8/355—Quinones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
- A61K8/65—Collagen; Gelatin; Keratin; Derivatives or degradation products thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/67—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
Definitions
- the present invention relates to a skin collagen production promoter that is effective in improving and / or preventing skin diseases, allergies, and aging, and more particularly to a food collagen-derived promoter that is highly safe from food.
- the skin is mainly divided into epidermis, dermis and subcutaneous tissue.
- the dermis is filled with a biological structure called an extracellular matrix composed of collagen, hyaluronic acid and the like to support the skin structure under the epidermis.
- This extracellular matrix component is produced by fibroblasts and the like.
- production of extracellular matrix components such as collagen is good, prevention of infection by bacteria and viruses, prevention of skin diseases, prevention of foreign substances such as allergens, maintenance of skin elasticity and moisture retention has been made.
- skin aging represented by symptoms such as spots, wrinkles, sagging, and rough skin progresses with a decrease in extracellular matrix components such as collagen.
- Patent Documents 1 to 14 Many materials that increase collagen in the skin have been reported (Patent Documents 1 to 14). However, most of them are not effective enough, have a very high production cost, and have insufficient food experience, so there are many problems in safety and the like.
- Vitamin K is generally regarded as a vitamin necessary for converting a glutamic acid residue specifically possessed by a vitamin K-dependent protein into ⁇ -carboxyglutamic acid (Gla).
- As vitamin K-dependent proteins several factors related to blood coagulation made in the liver, osteocalcin made from bone tissue, matrix Gla protein made from soft tissues such as blood vessels, and the like are known.
- Patent Documents 14 and 15 As skin effects of vitamin Ks, there are known skin conditions related to inflammation caused by anti-EGFR therapy and prevention and treatment of Rash (Patent Documents 14 and 15). It also treats skin diseases related to pigmentation such as melanin (Patent Document 16), effects on aza and bears in eyes (Non-Patent Documents 1 and 2), facial stains, dark spots under the eyes, redness, hot flashes, etc.
- Patent Document 17 A combination preparation of vitamin K and vitamin E (Patent Document 17) and a topical skin preparation (Literature 18) using a combination of lipoic acid and the like are known.
- Menaquinone-4 a kind of vitamin K2 is known to have an effect of increasing collagen in osteoblasts via an SXR receptor (Non-patent Document 3). It is also known that menaquinone-4 acts on a group of factors acting in a protein kinase A (protein kinase A) -dependent pathway (Non-patent Document 4).
- An object of the present invention is to provide a food ingredient or nutrient that is a safe food ingredient and has a food production promoting action in a small amount.
- the present inventors have intensively studied the physiological function of menaquinone-7 in vitamin K, which is contained in natto and has been ingested for a long time. Among them, the effect on skin cells was examined. Surprisingly, it was found that menaquinone-4 was not found in menaquinone-4, but only menaquinone-7 had an action to promote collagen production in skin cells, leading to the present invention. It was. That is, the present invention provides a skin collagen production promoter containing menaquinone-7 as an active ingredient.
- menaquinone-4 has no skin collagen production promoting action
- menaquinone-7 Has not been known to have a collagen production promoting action. It is surprising that the present invention can provide a skin collagen production promoter containing menaquinone-7 as an active ingredient.
- the present inventors have found that menaquinone-7 taken orally reaches a concentration that is an effective amount in the skin. Based on this finding, the present invention also provides a transdermal administration agent and an oral administration agent containing a skin collagen production promoter.
- Previously known skin collagen promoting compounds have not been shown to be distributed to the skin when taken orally.
- transdermal and oral administration agents containing skin collagen production promoter containing menaquinone-7 as an active ingredient have skin collagen increasing action. It is quite surprising to have
- Collagen production promoter containing menaquinone-7 of the present invention as an active ingredient is prevention of infection by bacteria and viruses, prevention of skin diseases, prevention of foreign substances such as allergens, skin aging, prevention / improvement of wrinkles, etc. Is extremely effective.
- the recommended amount of vitamin K that humans need per day is 55 to 80 ⁇ g (Japanese dietary intake standard 2010 version), but there is no allowable upper limit intake, and vitamin K is highly safe.
- menaquinone-7 is even safer because of its long-term intake from natto. Therefore, the collagen production promoter of the present invention is superior in safety to products conventionally known as a skin wrinkle improving / preventing agent or a skin aging improving / preventing agent.
- menaquinone-7 Since fat-soluble menaquinone-7 is more easily accumulated in the body than conventional collagen production promoters, it also has the effect that the action lasts longer. Menaquinone-7 is a very advantageous collagen production promoter because it can act as menaquinone-7 without being decomposed or metabolized even when taken orally.
- the collagen production promoter of the present invention can be used as a medicine, but it is extremely easy to take or use on a daily basis for supplements and cosmetics. Thus, skin aging and disease prevention are also contemplated.
- menaquinone-7 that can be used in the skin collagen production promoter of the present invention is a kind of vitamin K2.
- Vitamin K2 is classified from menaquinone-4 to MK-15, depending on the length of the isopronoid side chain.
- the skin collagen production promoter of the present invention contains vitamin K2 having an isoprenoid side chain length of 7 as an essential component.
- Menaquinone-7 is abundant in food as nutrients, and can be obtained from microorganisms such as those derived from natto and Bacillus natto, Bacillus subtilis, and lactic acid bacteria. Menaquinone-7 may be chemically synthesized in addition to the above.
- the content of menaquinone-7 in the skin collagen production promoter of the present invention varies depending on the form and intake of the composition, but it may usually be 0.00002 to 100% by weight, preferably 0.0003 to 70%. % By weight, more preferably in the range of 0.003 to 50% by weight. If the amount of menaquinone-7 is 0.00002% by weight or less, it may not be possible to take in an amount necessary for obtaining the skin collagen increasing effect.
- one or more conventionally known food ingredients having an effect of promoting skin collagen production may be added to the skin collagen production promoter of the present invention.
- the skin collagen production promoter of the present invention is used as a pharmaceutical, in addition to the essential component menaquinone-7 and an appropriate collagen acid-producing substance and collagen, collagen degradation products, amino acids, those commonly used as pharmaceutical aids May be added.
- general-purpose excipients disintegrants, binders, lubricants, vitamins, xanthine derivatives, pH adjusters, cooling agents, suspending agents, thickeners, dissolution Adjuncts, antioxidants, coating agents, plasticizers, surfactants, water, alcohols, water-soluble polymers, sweeteners, flavoring agents, acidulants, fragrances, colorants, etc. And can be added in quantitative ranges.
- the skin collagen production promoter of the present invention is used as a pharmaceutical, for solid preparations such as powders, granules, capsules, pills, tablets, chewable tablets, drops, drinks, liquids, suspensions. , Orally administered as a liquid such as emulsion, syrup and dry syrup, or transdermally administered as liquid, water, emulsion and cream.
- the ingestion method when the skin collagen production promoter of the present invention is used as a medicine is not particularly limited.
- oral intake transdermal intake, infusion, injection (intramuscular, intraperitoneal, subcutaneous, or intravenous).
- injection injection (intramuscular, intraperitoneal, subcutaneous, or intravenous).
- it is ingestion of tablets, capsules and the like in that the burden on the patient is small.
- the amount of intake may be appropriately set according to the symptoms.
- intake of menaquinone-7 per day The amount may be 10 ⁇ g to 100 mg, preferably 20 ⁇ g to 100 mg, more preferably 5 to 50 mg.
- 1 to 150 mg can be used.
- the skin collagen production promoter of the present invention is used as a cosmetic, in addition to the essential component menaquinone-7 and appropriate skin collagen production substances, amino acids as collagen raw materials, collagen degradation products, collagen, gelatin, You may add what is used widely as an auxiliary agent.
- ethylene glycol polyethylene glycol, propylene glycol, 1,3-butylene glycol, 1,4-butylene glycol, dipropylene glycol, glycerin, diglycerin, polyglycerin, pentylene glycol, isoprene glycol, glucose, maltose, fructose, Polyhydric alcohols such as xylitol, sorbitol, maltotriose, erythritol; lower alcohols such as methanol, ethanol, propyl alcohol, isopropyl alcohol, butyl alcohol, isobutyl alcohol; oleic acid, isostearic acid, lauric acid, myristic acid, palmitic acid, Higher fatty acids such as stearic acid, behenic acid, undecylenic acid; olive oil, corn oil, camellia oil, macadamia nut oil Oils such as avocado oil, rapeseed oil, sesame oil, castor oil, sa
- Nonionic surfactants alkyl sulfate salts, anionic surfactants such as sodium normal dodecylbenzenesulfonate, cationic surfactants such as polyoxyethylene dodecyl monomethylammonium chloride; steroidal and nonsteroidal anti-inflammatory agents; vitamins A, vitamin D, vitamin E, vitamin F, vitamins of the vitamin K group (other than menaquinone-7), pyridoxine dicaprylate, pyridoxine dipalmitate, ascorbyl dipalmitate, monopalmiti Vitamin derivatives such as ascorbyl monophosphate and ascorbyl monostearate; antioxidants such as flavonoids and carotenoids; higher aliphatic hydrocarbons such as squalane, squalene and liquid paraffin; sphingolipids such as ceramide, cerebroside and sphingomyelin; cholesterol; Sterols such as phytosterol; silicones such as methylpolysiloxane, methylphenylpoly
- transdermal administration agents such as liquids, solutions, emulsions, emulsions, creams, powders, powders, granules, capsules, pills, tablets It is processed into oral dosage forms such as solid preparations such as chewable tablets and drops, and liquid preparations such as drinks, solutions, suspensions, emulsions, syrups and dry syrups.
- the ingestion method when the skin collagen production promoter of the present invention is used as a cosmetic is oral intake or transdermal intake. From the viewpoint of immediate effect as a cosmetic, transdermal administration with a solution, emulsion, emulsion or cream is preferred.
- the intake amount (application amount) of menaquinone-7 per day is preferably 0.001 to 100 mg, more preferably 0.05 to 50 mg.
- the skin collagen production promoter of the present invention is used as a supplement, in addition to the essential component menaquinone-7 and other collagen-increasing substances as appropriate, those commonly used as supplement additives may be added.
- those commonly used as supplement additives may be added.
- general-purpose excipients, disintegrants, binders, lubricants, vitamins, xanthine derivatives, amino acids, pH adjusters, cooling agents, suspending agents, viscous agents, depending on the form of the oral administration agent Solubilizers, antioxidants, coating agents, plasticizers, surfactants, water, alcohols, water-soluble polymers, sweeteners, corrigents, acidulants, fragrances, colorants, etc. do not impair the effects of the invention It is possible to add in qualitative and quantitative ranges.
- the skin collagen production promoter of the present invention is processed into an oral administration agent different from ordinary foods such as powders, granules, capsules, pills, tablets, chewable tablets, and drops.
- the intake amount of menaquinone-7 per day is preferably 0.01 to 50 mg in consideration of safety. More preferred is ⁇ 1 mg.
- Example 1 Using normal human fibroblasts, the action of menaquinone-7 to promote skin collagen production was compared with vitamin K1 and menaquinone-4. Menaquinone-7 reagent (Wako Pure Chemical Industries, Ltd.) was tested for purity by HPLC. The set concentration was compared with a maximum solubility of 1.5 ⁇ 10 ⁇ 5 M of vitamin Ks in the cell culture system. The purity of vitamin K1 (Wako Pure Chemical Industries, Ltd.) and menaquinone-4 (Sigma) was tested by HPLC.
- Test Method Normal human dermal fibroblasts (manufactured by Kurabo Industries, Inc.) with a density of 2.0 ⁇ 10 4 cells per well using Dulbecco's Modified Eagle Medium (DMEM) (Sigma) containing 0.5% by weight of calf serum (FBS) It seed
- DMEM Dulbecco's Modified Eagle Medium
- FBS calf serum
- ascorbic acid magnesium phosphate (VC-PMg) was used as a positive control, and it was confirmed that there was no problem in the test method.
- the medium supernatant was collected and subjected to an ELISA for measuring the amount of type I collagen.
- the cells were lysed with 0.5% Triton X-100 solution, and the amount of protein was quantified.
- a phosphate-citrate buffer (0,0) containing 0.3 mg / ml 2,2′-Azinobis (3-ethylbenzothiazoline-6-sulfonic acid) diammonium salt (ABTS) and 0.03% hydrogen peroxide. .1M, pH 4.0) solution was added and reacted for 20 minutes, and the absorbance at 405 nm was measured with a microplate reader.
- the amount of type I collagen in the medium is calculated as the amount of type I collagen per unit protein by converting from the calibration curve measured on the same ELISA plate and dividing the amount of type I collagen in the medium by the amount of protein in all cells. did.
- menaquinone-7 MK-7 in FIG. 1
- Menaquinone-4 MK-4 in FIG. 1
- 6.0 ⁇ 10 ⁇ 5 M which is four times that amount, but the amount of collagen production did not increase at all.
- menaquinone-7 significantly promotes type I collagen production in human dermal fibroblasts even at a low concentration of 0.5 ⁇ 10 ⁇ 6 M.
- Example 3 Wistar rats male, 5 weeks old were allowed to acclimatize the purified diet AIN93G (produced by Oriental Yeast Co., Ltd.) for 1 week and then divided into 3 groups per group so that the weight between groups was uniform. .
- menaquinone-7 By ingesting 150 ⁇ g / g of menaquinone-7 diet, menaquinone-7 exceeding the concentration of menaquinone-7 necessary for promoting collagen production (0.5 ⁇ 10 ⁇ 6 M: 325 ng / g) was detected in the skin tissue. This suggests that menaquinone-7 is a promising route of administration by oral intake.
- Example 4 Four week old Crl: CD (SD) (SPF) male rats were acclimated until the start of administration, including a quarantine period of one week after arrival. During the quarantine / acclimation period, general conditions were observed every day, and the body weight was measured on the 1st (the day after arrival), the 3rd and the 7th. Each group was divided into 4 groups to 5 animals so that the weight between groups was uniform.
- menaquinone-7 Three types of feed with menaquinone-7 added to rat standard diet AIN93G: high MK7 diet (menaquinone-7: 45.4 ⁇ g / g diet), medium MK7 diet (menaquinone-7: 15 ⁇ g / g diet), and low MK7
- the meal menaquinone-7: 4.54 ⁇ g / g meal
- the MK7-free meal were freely ingested for 90 days.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Dermatology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Toxicology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Description
正常ヒト線維芽細胞を用いて、メナキノン-7の皮膚コラーゲン産生促進作用をビタミンK1およびメナキノン-4と比較した。メナキノン-7試薬(和光純薬工業株式会社)は、HPLCで純度検定したものを使用した。設定濃度は、細胞培養系におけるビタミンK類の最大溶解度1.5x10-5Mで比較した。ビタミンK1(和光純薬工業株式会社)およびメナキノン-4(Sigma社)の純度はHPLC法により検定したものを使用した。
正常ヒト真皮線維芽細胞(クラボウ社製)を0.5重量%仔牛血清(FBS)含有ダルベッコ改変イーグル培地(DMEM)(Sigma社)を用いて1ウェル当たり2.0x104個の細胞密度となるように96穴マイクロプレートに播種した。播種48時間後、表5に記載の濃度のメナキノン-7を含有する0.5重量%FBS含有DMEMと交換した。メナキノン-7は、エタノールに溶解した後、0.5%FBS含有DMEMにて100倍希釈した溶液を試験最高濃度液として調製した。また、陽性コントロールとしてアスコルビン酸リン酸マグネシウム塩(VC-PMg)を用い、試験方法に問題がないことを確認した。48時間試料含有培地で培養した後、培地上清を回収してI型コラーゲン量測定のELISAに供した。細胞は0.5%Triton X-100溶液にて溶解後、タンパク量を定量した。
培地および検量線用I型コラーゲン溶液を高吸着型ELISAプレートの各ウェルに入れ、37℃にて2時間コーティングした後、1%牛血清アルブミン(BSA)溶液を用いて37℃にて1時間ブロッキングした。一次抗体反応は、Anti-Human Collagen Type I antibody (Rabbit)を0.3%BSA溶液で希釈し、37℃にて1時間反応させた。ニ次抗体反応は、ヒストファインMAX-PO(R)(Rabbit)をリン酸緩衝液で希釈し、37℃にて1時間反応させた。次に、0.3mg/mlの2,2’-Azinobis(3-ethylbenzothiazoline-6-sulfonic acid)diammounium salt (ABTS)および0.03%の過酸化水素を含むリン酸-クエン酸緩衝液(0.1M,pH 4.0)溶液を加えて20分間反応させ、マイクロプレートリーダーにて405nmの吸光度を測定した。
表5に示す濃度範囲のメナキノン-7におけるヒト真皮線維芽細胞に対するコラーゲン産生促進作用を調べた。結果を表5に示す。試料添加は各群n=6で試験を実施し、結果はそれぞれの平均値で示している。なお、統計処理については、試料未添加の対照群に対するStudent t検定を実施し、1%未満の危険率の場合*をつけた。
Wistar系ラット(雄、5週齢)を、精製飼料AIN93G(オリエンタル酵母社製)を1週間自由に摂取させ馴化した後、群間の体重が均一になるように1群3匹に群分けした。ラット標準食(AIN93G)と、メナキノン-7を添加したメナキノン-7添加飼料(メナキノン-7:150μg/g)を各群3匹ずつのラットに、90日間自由摂取させた後、皮膚中のビタミンK濃度を測定した。ビタミンKの分析は、高速液体クロマトグラフィーを用い、白金黒を用いたポストカラム還元蛍光検出法により分析した(Sato et al.Biochim.Biophys.Acta 1622,145-150)。結果を表6に示す。
4週齢のCrl:CD(SD)(SPF)雄ラットを、入荷後1週間の検疫期間を含め投与開始まで馴化した。検疫・馴化期間中、一般状態観察を毎日行い、体重を入荷後1日(入荷翌日)、3日及び7日に測定した。群間の体重が均一になるように1群5匹に4群に群わけをした。
Claims (3)
- メナキノン-7を有効成分として含有する皮膚コラーゲン産生促進剤。
- 請求項1に記載の皮膚コラーゲン産生促進剤を含む経皮投与剤。
- 請求項1に記載の皮膚コラーゲン産生促進剤を含む経口投与剤。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP11858921.7A EP2561869B1 (en) | 2011-02-14 | 2011-08-09 | Skin collagen production promoter |
JP2012503560A JP5062922B2 (ja) | 2011-02-14 | 2011-08-09 | 皮膚コラーゲン産生促進剤 |
KR1020137024186A KR101781671B1 (ko) | 2011-02-14 | 2011-08-09 | 피부 콜라겐 산생 촉진제 |
BR112012027864A BR112012027864A2 (pt) | 2011-02-14 | 2011-08-09 | agente de elevação do teor de colágeno na pele |
CN201180067097.2A CN103347505B (zh) | 2011-02-14 | 2011-08-09 | 皮肤胶原蛋白增强剂 |
US13/644,210 US20130137640A1 (en) | 2011-02-14 | 2012-10-03 | Skin Collagen Enhancing Agent |
US14/623,243 US9522109B2 (en) | 2011-02-14 | 2015-02-16 | Skin collagen enhancing agent |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2011028189 | 2011-02-14 | ||
JP2011-028189 | 2011-02-14 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US13/644,210 Continuation US20130137640A1 (en) | 2011-02-14 | 2012-10-03 | Skin Collagen Enhancing Agent |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2012111187A1 true WO2012111187A1 (ja) | 2012-08-23 |
Family
ID=46672141
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2011/068123 WO2012111187A1 (ja) | 2011-02-14 | 2011-08-09 | 皮膚コラーゲン産生促進剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20130137640A1 (ja) |
EP (1) | EP2561869B1 (ja) |
JP (1) | JP5062922B2 (ja) |
KR (1) | KR101781671B1 (ja) |
CN (1) | CN103347505B (ja) |
BR (1) | BR112012027864A2 (ja) |
WO (1) | WO2012111187A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014017145A1 (ja) * | 2012-07-24 | 2014-01-30 | 株式会社J-オイルミルズ | 組成物 |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104188961A (zh) * | 2014-09-17 | 2014-12-10 | 朱忠良 | 一种皮肤胶原蛋白增强剂及其应用 |
EP3250180A2 (en) | 2015-01-27 | 2017-12-06 | VitaK B.V. | Epidermal skin health |
US10660847B2 (en) | 2017-03-17 | 2020-05-26 | Mary Kay Inc. | Cosmetic compositions and methods |
EP3427727B1 (de) * | 2017-07-14 | 2022-12-28 | BioActive Food GmbH | Kombination von biologisch aktiven substanzen zur stabilisierung oder erhöhung des kollagengehalts |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS647541A (en) | 1987-06-30 | 1989-01-11 | Toshiba Corp | Manufacture of semiconductor device |
JPH01135455A (ja) | 1987-11-20 | 1989-05-29 | Sanwa Tekki Corp | タンクの内面バフ研磨装置 |
JPH05320039A (ja) * | 1991-09-20 | 1993-12-03 | Taiyo Kagaku Co Ltd | 美白化粧料 |
WO2002080862A1 (fr) * | 2001-04-06 | 2002-10-17 | Toyo Hakko Co., Ltd. | Materiaux cosmetiques et leur procede de production |
JP2004196759A (ja) | 2002-12-18 | 2004-07-15 | Takashi Suzuki | ビタミンk類とビタミンe複合の美肌化粧料 |
JP2007091637A (ja) | 2005-09-29 | 2007-04-12 | Fancl Corp | I型コラーゲン産生促進用組成物 |
JP2007186471A (ja) | 2006-01-16 | 2007-07-26 | Shiseido Co Ltd | I型コラーゲン産生促進剤および抗しわ剤 |
JP2008094750A (ja) | 2006-10-11 | 2008-04-24 | Toyo Beauty Kk | コラーゲン産生促進剤および抗老化化粧料 |
JP2008133270A (ja) | 2006-10-31 | 2008-06-12 | Yamada Bee Farm Corp | コラーゲンとヒアルロン酸の産生促進剤 |
JP2008189607A (ja) | 2007-02-06 | 2008-08-21 | Tama Seikagaku Kk | I型コラーゲン産生促進剤及び皮膚外用剤 |
JP2008260747A (ja) | 2007-03-19 | 2008-10-30 | Kinjirushi Kk | コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品 |
JP2008280296A (ja) | 2007-05-11 | 2008-11-20 | Nippon Menaade Keshohin Kk | コラーゲン生成促進及び分解抑制剤 |
WO2009063485A2 (en) | 2007-07-24 | 2009-05-22 | Viridis Biopharma Pvt Ltd. | Treatment of human disease conditions and disorders using vitamin k analogues and derivatives |
JP2009184997A (ja) | 2008-02-08 | 2009-08-20 | B & C Laboratories Inc | コラーゲン産生促進剤 |
US20090234022A1 (en) | 2008-03-13 | 2009-09-17 | Hana Biosciences, Inc. | Formulations of vitamin K analogs for topical use |
US20090239952A1 (en) | 2005-04-15 | 2009-09-24 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
JP2009249366A (ja) | 2008-04-10 | 2009-10-29 | Kose Corp | コラーゲン産生促進剤、及び老化防止用皮膚外用剤 |
JP2009298724A (ja) | 2008-06-12 | 2009-12-24 | Hinoki Shinyaku Kk | コラーゲン産生促進剤及び皮膚外用剤 |
JP2010095499A (ja) | 2008-10-20 | 2010-04-30 | Unitika Ltd | コラーゲン産生促進剤 |
JP2010215648A (ja) | 2003-10-08 | 2010-09-30 | Otsuka Pharmaceut Co Ltd | コラーゲン産生促進用組成物 |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2900238B2 (ja) * | 1994-07-07 | 1999-06-02 | 株式会社ホーネンコーポレーション | 天然メナキノン−7高含量脂質 |
JPH107541A (ja) | 1996-06-20 | 1998-01-13 | Noevir Co Ltd | 皮膚外用剤 |
JPH1135455A (ja) | 1997-07-18 | 1999-02-09 | Noevir Co Ltd | コラーゲン産生促進剤、及びこれを含有する皮膚の老化防止用又は創傷治癒促進用皮膚外用剤 |
JP2000256176A (ja) * | 1999-03-02 | 2000-09-19 | Shalom:Kk | 皮膚化粧料 |
US20040023560A1 (en) | 2002-08-05 | 2004-02-05 | Swoboda Gary L. | Apparatus and method for a reversible emulator/target cable connector |
WO2005030190A1 (en) * | 2003-09-26 | 2005-04-07 | Natural Asa | Natural menaquinone 7 compositions |
EP2130533A4 (en) | 2007-04-05 | 2010-04-21 | J Oil Mills Inc | ATARACTIC AND FUNCTIONAL FOOD |
JP5320039B2 (ja) | 2008-11-26 | 2013-10-23 | 花王株式会社 | サーマルインクジェット記録用水分散体の製造方法 |
-
2011
- 2011-08-09 CN CN201180067097.2A patent/CN103347505B/zh not_active Expired - Fee Related
- 2011-08-09 BR BR112012027864A patent/BR112012027864A2/pt not_active Application Discontinuation
- 2011-08-09 EP EP11858921.7A patent/EP2561869B1/en not_active Not-in-force
- 2011-08-09 WO PCT/JP2011/068123 patent/WO2012111187A1/ja active Application Filing
- 2011-08-09 JP JP2012503560A patent/JP5062922B2/ja active Active
- 2011-08-09 KR KR1020137024186A patent/KR101781671B1/ko active IP Right Grant
-
2012
- 2012-10-03 US US13/644,210 patent/US20130137640A1/en not_active Abandoned
-
2015
- 2015-02-16 US US14/623,243 patent/US9522109B2/en not_active Expired - Fee Related
Patent Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS647541A (en) | 1987-06-30 | 1989-01-11 | Toshiba Corp | Manufacture of semiconductor device |
JPH01135455A (ja) | 1987-11-20 | 1989-05-29 | Sanwa Tekki Corp | タンクの内面バフ研磨装置 |
JPH05320039A (ja) * | 1991-09-20 | 1993-12-03 | Taiyo Kagaku Co Ltd | 美白化粧料 |
WO2002080862A1 (fr) * | 2001-04-06 | 2002-10-17 | Toyo Hakko Co., Ltd. | Materiaux cosmetiques et leur procede de production |
JP2004196759A (ja) | 2002-12-18 | 2004-07-15 | Takashi Suzuki | ビタミンk類とビタミンe複合の美肌化粧料 |
JP2010215648A (ja) | 2003-10-08 | 2010-09-30 | Otsuka Pharmaceut Co Ltd | コラーゲン産生促進用組成物 |
US20090239952A1 (en) | 2005-04-15 | 2009-09-24 | Albert Einstein College Of Medicine Of Yeshiva University | Vitamin k for prevention and treatment of skin rash secondary to anti-egfr therapy |
JP2007091637A (ja) | 2005-09-29 | 2007-04-12 | Fancl Corp | I型コラーゲン産生促進用組成物 |
JP2007186471A (ja) | 2006-01-16 | 2007-07-26 | Shiseido Co Ltd | I型コラーゲン産生促進剤および抗しわ剤 |
JP2008094750A (ja) | 2006-10-11 | 2008-04-24 | Toyo Beauty Kk | コラーゲン産生促進剤および抗老化化粧料 |
JP2008133270A (ja) | 2006-10-31 | 2008-06-12 | Yamada Bee Farm Corp | コラーゲンとヒアルロン酸の産生促進剤 |
JP2008189607A (ja) | 2007-02-06 | 2008-08-21 | Tama Seikagaku Kk | I型コラーゲン産生促進剤及び皮膚外用剤 |
JP2008260747A (ja) | 2007-03-19 | 2008-10-30 | Kinjirushi Kk | コラーゲン産生促進剤、促進方法、香粧品、飲食品および医薬品 |
JP2008280296A (ja) | 2007-05-11 | 2008-11-20 | Nippon Menaade Keshohin Kk | コラーゲン生成促進及び分解抑制剤 |
WO2009063485A2 (en) | 2007-07-24 | 2009-05-22 | Viridis Biopharma Pvt Ltd. | Treatment of human disease conditions and disorders using vitamin k analogues and derivatives |
JP2009184997A (ja) | 2008-02-08 | 2009-08-20 | B & C Laboratories Inc | コラーゲン産生促進剤 |
US20090234022A1 (en) | 2008-03-13 | 2009-09-17 | Hana Biosciences, Inc. | Formulations of vitamin K analogs for topical use |
JP2009249366A (ja) | 2008-04-10 | 2009-10-29 | Kose Corp | コラーゲン産生促進剤、及び老化防止用皮膚外用剤 |
JP2009298724A (ja) | 2008-06-12 | 2009-12-24 | Hinoki Shinyaku Kk | コラーゲン産生促進剤及び皮膚外用剤 |
JP2010095499A (ja) | 2008-10-20 | 2010-04-30 | Unitika Ltd | コラーゲン産生促進剤 |
Non-Patent Citations (10)
Title |
---|
AICHI-KEN SANGYO GIJUTSU KENKYUSHO KENKYU HOKOKU, no. 2, 2003, pages 132 - 133, XP008158239 * |
BOND, M. ET AL.: "Nuclear factor kB activity is essential for matrix metalloproteinase-1 and -3 upregulation in rabit dermal fibroblasts", BIOCHEM. BIOPHYS. RES. COMMUN., vol. 264, 1999, pages 561 - 567, XP008158204 * |
ELSON, M. ET AL., COSMET. DERMATOL., vol. 12, 1999, pages 32 - 34 |
ELSON, M. ET AL., COSMET. DERMATOL., vol. 8, 1995, pages 25 - 27 |
ICHIKAWA ET AL., J. BIOL. CHEM., vol. 281, no. 25, 2006, pages 16927 - 34 |
ICHIKAWA ET AL., J. MOL. ENDOCRINOL., vol. 39, 2007, pages 239 - 47 |
IDE, Y. ET AL.: "Inhibition of matrix metalloproteinase expression by menatetrenone, a vitamin K2 analogue", ONCOL. REP., vol. 22, 2009, pages 599 - 604, XP008158201 * |
SATO ET AL., BIOCHIM. BIOPHYS. ACTA, vol. 1622, 2003, pages 145 - 150 |
See also references of EP2561869A4 * |
VITAMIN, vol. 80, no. 4, 2006, pages 203, XP008158244 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014017145A1 (ja) * | 2012-07-24 | 2014-01-30 | 株式会社J-オイルミルズ | 組成物 |
JP5483786B1 (ja) * | 2012-07-24 | 2014-05-07 | 株式会社J−オイルミルズ | 組成物 |
US9486398B2 (en) | 2012-07-24 | 2016-11-08 | J-Oil Mills, Inc. | Composition |
CN108057117A (zh) * | 2012-07-24 | 2018-05-22 | J-制油株式会社 | 包含胶原蛋白水解物的组合物的用途 |
US10039704B2 (en) | 2012-07-24 | 2018-08-07 | J-Oil Mills, Inc. | Composition |
CN108057117B (zh) * | 2012-07-24 | 2021-05-18 | J-制油株式会社 | 包含胶原蛋白水解物的组合物的用途 |
Also Published As
Publication number | Publication date |
---|---|
US20150164767A1 (en) | 2015-06-18 |
KR101781671B1 (ko) | 2017-09-25 |
EP2561869A1 (en) | 2013-02-27 |
JP5062922B2 (ja) | 2012-10-31 |
CN103347505B (zh) | 2015-02-04 |
JPWO2012111187A1 (ja) | 2014-07-03 |
KR20140012990A (ko) | 2014-02-04 |
BR112012027864A2 (pt) | 2016-08-09 |
CN103347505A (zh) | 2013-10-09 |
EP2561869A4 (en) | 2013-09-04 |
EP2561869B1 (en) | 2016-12-14 |
US9522109B2 (en) | 2016-12-20 |
US20130137640A1 (en) | 2013-05-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9522109B2 (en) | Skin collagen enhancing agent | |
US10039704B2 (en) | Composition | |
JP5241054B2 (ja) | コラーゲン合成促進用組成物 | |
US10500187B2 (en) | Composition comprising plant phenols for preventing or reducing TEWL and associated disorders and diseases | |
JP2005263794A (ja) | コラーゲン合成促進用組成物 | |
EP1285661B1 (en) | Use of an antioxidant comprising an extract of mozuku | |
WO2015015816A1 (ja) | 繊維芽細胞賦活剤 | |
KR20170112651A (ko) | 클로로겐산 및 루틴 화합물을 유효성분으로 포함하는 피부 주름 예방 또는 개선용 조성물 | |
JPWO2010150612A1 (ja) | ヒアルロン酸産生促進剤及びメラニン生成抑制剤 | |
EP3305370B1 (en) | Algae autophagy activator | |
JP2013126965A (ja) | 正常皮膚細胞用Nrf2活性化剤 | |
KR20230024679A (ko) | 메나퀴논-7을 유효 성분으로서 함유하는 콜라겐 산생 촉진제 | |
KR101819670B1 (ko) | 피부질환 예방 또는 치료용 조성물 | |
JP6920031B2 (ja) | 慢性角化型湿疹改善剤 | |
WO2015015815A1 (ja) | 繊維芽細胞賦活剤 | |
JP5520703B2 (ja) | コラーゲン合成促進用組成物 | |
JP7417347B2 (ja) | 慢性角化型湿疹改善剤 | |
JP2011207816A (ja) | コラーゲン産生促進剤 | |
JP2004075558A (ja) | 美白改善用キット |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 2012503560 Country of ref document: JP |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11858921 Country of ref document: EP Kind code of ref document: A1 |
|
REEP | Request for entry into the european phase |
Ref document number: 2011858921 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2011858921 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: BR Ref legal event code: B01A Ref document number: 112012027864 Country of ref document: BR |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 20137024186 Country of ref document: KR Kind code of ref document: A |
|
ENP | Entry into the national phase |
Ref document number: 112012027864 Country of ref document: BR Kind code of ref document: A2 Effective date: 20121030 |